Veliparib
Pre-clinicalCompletedDevelopment Stage
Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound
Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound, Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Cancer, Patients Requiring Veliparib Suspension Formulation
— → —
About Veliparib
Veliparib is a pre-clinical stage product being developed by AbbVie for Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound. The current trial status is completed. This product is registered under clinical trial identifier NCT03123211. Target conditions include Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound, Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Cancer.
Hype Score Breakdown
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03123211 | Pre-clinical | Completed |
| NCT03044795 | Phase 2 | Withdrawn |
| NCT01853306 | Phase 1 | Completed |
| NCT01123876 | Phase 1 | Completed |
Competing Products
20 competing products in Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound